¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Help - - Sign up - Phone number 902 888 740

2016 FI

© Thomson Reuters, Journal Citation Reports, 2016

Indexed in:

Current Contents/Clinical Medicine, Journal Citation Reports, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, MEDES, PASCAL, SCOPUS, ScienceDirect


  • Impact Factor: 1,125(2016)
  • 5-years Impact Factor: 1,292
  • SCImago Journal Rank (SJR):0,221
  • Source Normalized Impact per Paper (SNIP):0,385

© Thomson Reuters, Journal Citation Reports, 2016

Med Clin 2001;117:147-57 - DOI: 10.1016/S0025-7753(01)72044-1
Nuevos tratamientos inmunodepresores de inducción en el trasplante renal
Julio Pascual, , Joaquín Ortuño
Servicio de Nefrología. Universidad de Alcalá. Hospital Ramón y Cajal. Madrid.
Received 18 December 2000, Accepted 02 March 2001
Palabras clave
Tratamiento de inducción, Trasplante renal, Anti-IL2r, Basiliximab, Daclizumab
This article is only available in PDF
M.D. Denton,C.C. Magee,M.H. Sayegh
Immunosuppressive strategies in transplantation
J. Pascual
Tratamiento inmunodepresor inicial en trasplante renal
Nefrología, 18 (1998), pp. 104-108
J. Michael,G.C. Francos,J.F. Burke,A. Besarab,M. Moritiz,D. Gillum
A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients
Transplantation, 46 (1989), pp. 805-808
D.P. Slakey,C.P. Johnson,R.D. Callaluce,B.J. Browne,R.Z. Yong,A.M. Roza
A prospective randomized comparison of quadruple versus triple tharapy for first cadaver transplants with immediate function
Transplantation, 56 (1993), pp. 827-831
A.S. Belitsky,A.S. MacDonald,A.D. Cohen,J. Croker,D. Hirsch,K. Jindal K
Comparison of antilymphocyte globulin and continuous iv cyclosporin A as induction immunosuppression for cadaver kidney transplants: a prospective randomized study
Transplant Proc, 23 (1991), pp. 999-1000
C. Banhegyi,S. Rockenschaub,F. Muhlbacher,J. Kovarik,P. Balcke,P. Gotzinger P
Preliminary results of a prospective randomized clinical trial comparing cylosporine A to antithymocyte globulin immunosuppressive induction therapy in kidney transplantation
Transplant Proc, 23 (1991), pp. 2207-2208
D. Thibaudin,E. Alamartine,J.P. De Filippis,N. Diab,B. Laurent,F. Berthoux
Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin
Nephrol Dial Transplant, 13 (1998), pp. 711-715
D.C. Brennan,K. Flavin,J.A. Lowell,T.K. Howard,S. Shenoy,S. Burgess
A randomized, double-blind comparison of thymoglobulin versus Atgam for induction immunosuppressive tharapy in adult renal transplant recipients
Transplantation, 67 (1999), pp. 1011-1018
R.L. Kirkman
New usage paradigms in antibody therapy: induction or true profilaxis?
Transplant Proc, 31 (1999), pp. 1234-1235
A.M. De Mattos,A.J. Olyaei,W.M. Bennett
Pharmacology of immunosuppressive medications used in renal diseases and transplantation
Am J Kidney Dis, 28 (1996), pp. 631-667
D. Abramowicz,L. Schandene,M. Goldman,A. Crusiaux,P. Vereerstraeten,L. De Pauw
Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients
Transplantation, 47 (1989), pp. 606-608
M.R. Costanzo-Nordin
Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema and cardiac dysfunction
Transplant Proc, 25 (1993), pp. 21-24
M. Goldman,D. Abramowicz,L. De Pauw,M.L. Alegre,I. Widera,P. Vereerstraeten
OKT3-induced cytokine release: attenuation by high-dose methylprednisolone
Lancet, 2 (1989), pp. 802-803
B. Carpentier,C. Hiesse,C. Ferran,O. Lantz,D. Fries,J.F. Bach,L. Chatenoud
Acute clinical syndrome associated with OKT3 administration: prevention by single injection of an anti-human TNF monoclonal antibody
Presse Med, 20 (1991), pp. 2009-2011
L. Schandene,C. Gerard,A. Crusiaux,D. Abramowicz,T. Velu,M. Goldman
Interleukin-10 inhibits OKT3-induced cytokine release: in vitro comparison with pentoxifylline
Transplant Proc, 25 (1993), pp. 55-56
C.F. Shield,L. Kahana,J. Pirsch,P. Vergne-Marini,M.R. First,T.J. Schroeder
Use of indomethacin to minimize the adverse reactions associated with Orthoclone OKT3 treatment of kidney allograft rejection
Transplantation, 54 (1992), pp. 164-165
M. Alegre,K. Gastaldello,D. Abramowicz,P. Kinnaert,P. Vereerstraeten,L. De Pauw
Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome
Transplantation, 52 (1991), pp. 674-679
D.J. Norman,J.A. Kimball,W.M. Bennett,F. Shihab,T.D. Batiuk,M.M. Meyer
A prospective, double-blind randomized study of high versus lowdose OKT3 induction immunosuppression in cadaveric renal transplantation
Transplant Int, 7 (1994), pp. 356-361
J.P. Soulillou
Relevant targets for therapy with monoclonal antibodies in allograft tranplantation
Kidney Int, 46 (1994), pp. 540-553
T. Batiuk,W.M. Bennett,M. Meyer,D.J. Norman
Cytokine nephropathy during antilymphocyte therapy
Transplant Proc, 25 (1993), pp. 27-30
G.L. Chan,S.S. Weinstein,C.E. Wright,V.D. Bowers,D.Y. Alveranga,D.L. Shires
Encephalopathy associated with OKT3 administration: possible interaction with indomethacin
Transplantation, 52 (1991), pp. 148-150
J.R. Thistlethwaite,J.K. Stuart,J.T. Mayes,A.O. Gaber,S. Woddle,M.R. Buckingham
Complications and monitoring of OKT3 therapy
Am J Kidney Dis, 11 (1988), pp. 112-119
C.S. Oh,R.J. Stratta,B.C. Fox,H.W. Sollinger,F.O. Belzer,D.G. Maki
Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation
Transplantation, 45 (1988), pp. 68-73
D.W. Hanto,M.D. Jendrisak,S.K.S. So,C.S. McCullough,T.M. Rush,S.M. Michalski
Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation
Transplantation, 57 (1994), pp. 377-384
E.H. Cole,D.C. Cattran,V.T. Farewell,M. Aprile,R.A. Bear,Y.P. Pei
A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection
Transplantation, 57 (1994), pp. 60-67
L.J. Swinnen,M.R. Costanzo-Nordin,S.G. Fisher,E.J. O’Sullivan,M.R. Johnson,Heroux
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac- transplant recipients
N Engl J Med, 323 (1990), pp. 1723-1728 http://dx.doi.org/10.1056/NEJM199012203232502
G. Opelz
for the Collaborative Transplant Study. Efficacy of rejection prophylaxis with OKT3 in renal transplantation
Transplantation, 60 (1995), pp. 1220-1224
L.A. Szczech,J.A. Berlin,H.I. Feldman
The effect of antilymphocyte induction therapy on renal allograft survival. A metaanalysis of individual patient data. Antilymphocyte Antibody Induction Therapy Study Group
Ann Intern Med, 128 (1998), pp. 817-826
J.M. Cecka,D. Gjertson,P.I. Terasaki
Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?
Transplant Proc, 25 (1993), pp. 548-549
D. Abramowicz,D.J. Norman,P. Vereerstraeten,M. Goldman,L. De Pauw,J.L. Vanherweghem
OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival
Kidney Int, 49 (1996), pp. 768-772
J.F. Neylan,the US Renal Transplant Mycophenolate Mofetil Study Group
Immunosuppressive therapy in high risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft patients
Transplantation, 64 (1997), pp. 1277-1282
Y. Lebranchu,P. Aubert,F. Bayle,J. Bedrossian,F. Berthoux,B. Bourbigot
Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One year results of a double blind, randomized, multicenter study comparing normal dose versus low dose and withdrawal of steroids
Transplant Proc, 32 (2000), pp. 396-397
A.D. Hibberd,J.H. Trevillian,J.H. Wlodarzcyk,A.M. Gillies,A.M. Stein,A.G.R. Sheil
Cancer risk associated with ATG/OKT3 in renal transplantation
Transplant Proc, 31 (1999), pp. 1271-1272
T.A. Waldmann
The interleukin-2 receptor
J Biol Chem, 266 (1991), pp. 2681-2684
T.A. Waldmann
The structure, function and expression of interleukin-2 receptors on normal and malignant lymphocytes
Science, 232 (1986), pp. 727-732
T. Uchiyama,S. Broder,T.A. Waldmann
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells
J Immunol, 123 (1981), pp. 1393-1397
T. Uchiyama,D.L. Nelson,T.A. Fleisher,T.A. Waldmann
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells
J Immunol, 126 (1981), pp. 1398-1403
W.J. Leonard,J.M. Depper,G.R. Crabtree,S. Rudikoff,J. Pumphrey,R.J. Robb
Molecular cloning and expression of cDNAs for the human interleukin- 2 receptor
Nature, 311 (1984), pp. 626-631
D. Cosman,D.P. Cerretti,A. Larsen,L. Park,C. March,S. Dowler
Cloning, sequence and expression of human interleukin-2 receptor
Nature, 312 (1984), pp. 768-771
T. Nikaido,A. Shimizu,N. Ishida,H. Sabe,K. Teshigawara,M. Maeda
Molecular cloning of cDNA encoding human interleukin-2 receptor
Nature, 311 (1984), pp. 631-635
T. Takeshita,H. Asao,K. Ohtani,N. Ishii,S. Kumaki,N. Tanaka
Cloning of the chain of the human IL-2 receptor
Science, 257 (1992), pp. 379-382
J.P. Soulillou,P. Peyronnet,B. Le Mauff,M. Hourmant,D. Olive,C. Mawas
Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin-2 receptor
Lancet, 1 (1987), pp. 1339-1342
J.P. Soulillou,D. Cantarovich,B. Le Mauff,M. Giral,N. Robillard,M. Hourmant
Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts
N Engl J Med, 322 (1990), pp. 1175-1182 http://dx.doi.org/10.1056/NEJM199004263221702
M. Hourmant,B. Le Mauff,D. Cantarovich,J. Dantal,R. Baatard,M. Denis
Prevention of acute rejection episodes with an anti-interleukin-2 receptor monoclonal antibody (II). Results after a second kidney transplantation
Transplantation, 57 (1994), pp. 204-207
D. Cantarovich,B. Le Mauff,M. Hourmant,J. Dantal,R. Baatard,M. Denis
Prevention of acute rejection episodes with an anti-interleukin-2 receptor monoclonal antibody. I. Results after combined pancreas and kidney transplantation
Transplantation, 57 (1994), pp. 198-203
R.L. Kirkman,M.E. Shapiro,C.B. Carpenter,D.B. McKay,E.L. Milford,E.L. Ramos
A randomized prospective trial of anti.Tac monoclonal antibody in human renal transplantation
Transplantation, 51 (1991), pp. 107-113
T. Van Gelder,R. Zietse,A.H. Mulder,J.N.M. Yzermans,C.J. Hesse,L.M.B. vaessen
A double-blind, placebo-controlled study of monoclonal antiinterleukin- 2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation
Transplantation, 60 (1995), pp. 248-252
P.T. Jones,P.H. Dear,J. Foote,M.S. Neuberger,G. Winter
Replacing the complementary-determining regions in a human antibody with those from a mouse
Nature, 321 (1986), pp. 522-525 http://dx.doi.org/10.1038/321522a0
R.P. Junghans,T.A. Waldmann,N.F. Landolfi,N.M. Avdalovic,W.P. Schneider,C. Queen,Anti-Tac-H
a humanized antibody to the interleukin-2 receptor with new features for immunotherapy in malignant and immune disorders
Cancer Res, 50 (1990), pp. 1495-1502
C. Queen,W.P. Schneider,H.E. Selick,P.W. Payne,N.F. Landolfi,J.F. Duncan
A humanized antibody that binds to the interleukin 2 receptor
Proc Natl Acad Sci USA, 86 (1989), pp. 10029-10033
P.L. Amlot,E. Rawlings,O.N. Fernando,P.J. Griffin,G. Heinrich,M.H. Schreier
Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
Transplantation, 60 (1995), pp. 748-756
J.M. Kovarik,E. Rawlings,P. Sweny,O. Fernando,R. Moore,P.J. Griffin
Pharmacokinetics and immunodynamics of himeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients
Transplant Int, 9 (1996), pp. 32-33
J. Kovarik,P. Wolf,J.M. Cisterne,G. Mourad,Y. Lebranchu,P. Lang
Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts
Transplantation, 64 (1997), pp. 1701-1705
J. Kovarik,M. Mentser,P. Broyer,C. Loirat,J. Crocker,G. Offner
Disposition of basiliximab, a chimeric IL-2 receptor (CD25) monoclonal antibody, in pediatric renal transplant patients [resumen]
Transplantation, 65 (1998), pp. S66
B. Nashan,R. Moore,P. Amlot,A.G. Schmidt,K. Abeywickrama,J.P. Soulillou
for the CHIB 201 International Study Group
Lancet, 350 (1997), pp. 1193-1198
B.D. Kahan,P.R. Rajagopalan,M. Hall,for the United States Simulect Renal Study Group
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliimab, a chimeric antiinterleukin- 2 receptor monoclonal antibody
Transplantation, 67 (1999), pp. 276-284
J. Pascual,J. García,J.J. Amenabar,M. Arias,A. Sánchez
Andrés I por el grupo de estudio de Simulect en fase IV. Basiliximab (Simulect®) disminuye significativamente la incidencia de rechazo agudo en pacientes receptores de trasplante renal que reciben terapia triple con azatioprina [resumen]
Nefrología, 20 (2000), pp. 66
F. Oppenheimer,M. González-Molina,J.M. Morales,I. Andres,por el Simulect International Study Group
Basiliximab (Simulect®) es seguro y eficaz en combinación con terapia triple de Sandimmun Neoral®, esteroides y Cellcept® en pacientes receptores de trasplante renal [resumen]
Nefrología, 20 (2000), pp. 66
J.E. Hartle,J.E. Bisordi,S. Chao,M.J. Freeland,J.C. West
The addition of basiliximab to cellcept, neoral and steroids resulted in a significant reduction in acute renal allograft rejection [resumen]
Transplantation, 69 (2000), pp. S159
R.K. Kode,O. Pankewycz,K. Ranganna,D. Sierka,M. Ardron,A.M.S. Kumar
Rapid steroid reduction in kidney transplant recipients with Simulect, neoral and cellcept [resumen]
Transplantation, 69 (2000), pp. S224
J.M. Grinyo,J.M. Cruzado,S. Gil-Vernet,D. Serón,I. Andrés
por el Grupo de Estudio Internacional de Simulect. Retirada rápida de esteroides versus una pauta de esteroides estándar en pacientes tratados con Simulect®, Sandimmun Neoral® y micofenolato mofetil para la prevención del rechazo agudo en trasplante renal [resumen]
Nefrología, 20 (2000), pp. 66
H. Shidban,M. Sabawi,S. Aswad,G. Chambers,I. Castillon,R. Naraghi
Controlled trial of IL-2R antibody basiliximab (Simulect) versus low dose OKT3 in cadaver kidney transplant recipients [resumen]
Transplantation, 69 (2000), pp. S156
S.M. Flechner,D. Goldfarb,R. Fairchild,D. Cook,B. Mastroianni,R. Fisher
A randomized prospective trial of OKT3 vs basiliximab for induction therapy in renal transplantation [resumen]
Transplantation, 69 (2000), pp. S157
R.P. Pelletier,E.A. Davies,E.A. Elkhammas,G.L. Bumgardner,M.L. Henry,R.M. Ferguson
Improved outcome in renal transplant recipients treated with Simulect versus OKT3 induction [resumen]
Transplantation, 69 (2000), pp. S157
R.K. Kode,A.M.S. Kumar,O. Pankewycz,B. Fyfe,S. Stabler,K. Ranganna
Simulect induction is safer and more effective than OKT3 in kidney recipients older than 60 years [resumen]
Transplantation, 69 (2000), pp. S157
S. Chowdhury,R. Kode,K. Ranganna,B. Fyfe,S. Stabler,A. Damask
Induction strategy using basiliximab combined with mycophenolate and immediate low dose cyclosporin is steroid sparing and more effective than OKT3 [resumen]
Transplantation, 69 (2000), pp. S159
I. Ahmad,B. Ketel,G. Barone,Y. Barri,K. Reed,G. Almquist
Comparison of basiliimab to rabbit anti-thymocyte globulin induction in kidney transplant recipients [resumen]
Transplantation, 69 (2000), pp. S159
Y. Lebranchu,B. Hirault de Ligny,O. Toupance,G. Touchard,Y. Lemeur,I. Etienne
A multicenter, randomized trial of Simulect® versus Thymoglobuline ® in renal transplantation [resumen]
Tranplantation, 69 (2000), pp. S258
G. Offner,M. Broyer,C. Loirat,M. Mentser,J. Lemire,J.F.S. Crocker
Multicenter study of the safety and tolerability of basiliximab (Simulect®) in de novo pediatric renal transplantation [resumen]
Transplantation, 69 (2000), pp. S258
R.A. Cohn,J.R. Sherbotie,P.C. Grimm,J. Leone,R. Taylor,T. Somerville
Basiliximab (Simulect®) dramatically reduces acute rejection after pediatric kidney transplantation [resumen]
Transplantation, 69 (2000), pp. S260
J. Strehlau,L. Pape,G. Offner,B. Nashan,J.H.H. Ehrich
Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients
Lancet, 356 (2000), pp. 1327-1328
B. Philosophe,J.C. Fink,A.M. Wiland,A.C. Farney,E.J. Schweitzer,J.O. Colonna
Low kidney rejection rates with basiliximab induction and delayed introduction of tacrolimus for patients with delayed graft function [resumen]
Transplantation, 69 (2000), pp. S259
J.C. Hong,B.D. Kahan
A calcimeurin-free strategy for induction immunosuppression for delayed graft function in cadaveric kidney transplantation [resumen]
Transplantation, 69 (2000), pp. S259
J.R. Thistlethwaite,B. Nashan,M. Hall,L. Chodof,T.H. Lin,on behalf of the Global Simulect Study Group
Reduced acute rejection and superior 1- year renal allograft survival with basiliximab in patients with diabetes mellitus
Transplantation, 70 (2000), pp. 784-790
E.A. Elkhammas,M.L. Henry,A. Demirag,M.M. Carmona,G.L. Bumgardner,R.P. Pelletier
Basiliximab vs OKT3 in primary simultaneous pancreaskidney transplant recipients [resumen]
Transplantation, 69 (2000), pp. S407
J. Odorico,E. Elkhammas,A. Secchi,P. Rigotti,K. Somberg,D. Girault
A multicenter trial of Simulect® in combination with Neoral®, Cellcept® and steroids for the prevention of acute rejection in kidney-pancreas transplantation: a low rate of rejection without recurrent diabetes mellitus [resumen]
Transplantation, 69 (2000), pp. S409
J.P. Leone,R.J. Taylor
Basiliximab induction versus no induction in simultaneous kidney pancreas transplantation using mycophenolate/tacrolimus/ prednisone maintenance immunosuppression [resumen]
Transplantation, 69 (2000), pp. S410
J. Hakimi,R. Chizzonite,D.R. Luke,P.C. Familletti,P. Bailon,J.A. Kondas
Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys
J Immunol, 147 (1991), pp. 1352-1359
P.S. Brown,G.L. Parenteau,F.M. Dirba,R.J. Garsia,C.K. Goldman,M. Bukowski
Anti-Tac-H, a humanized antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival
Proc Natl Acad Sci USA, 88 (1991), pp. 2663-2667
F. Vincenti,M. Lantz,J. Birnbaum,M. Garovoy,D. Mould,J. Hakimi
A phase I trial of humanized anti-interleukin-2 receptor antibody in renal transplantation
Transplantation, 63 (1997), pp. 33-38
F. Vincenti,R. Kirkman,S. Light,G. Bumgardner,M. Pescovitz,P. Halloran
for the Daclizumab Triple Therapy Study Group Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
N Engl J Med, 338 (1998), pp. 161-165 http://dx.doi.org/10.1056/NEJM199801153380304
B. Nashan,S. Light,I.R. Hardie,A. Lin,J.R. Johnson,for the Daclizumab Double Therapy Study Group
Reduction of acute renal allograft rejection by daclizumab
Transplantation, 67 (1999), pp. 110-115
P. Hengster,M.D. Pescovitz,D. Hyatt,R. Margreiter,on behalf of the Roche Study Group
Cytomegalovirus infections after treatment with daclizumab, an anti-IL-2 receptor antibody, for prevention of renal allograft rejection
Transplantation, 68 (1999), pp. 310-313
F. Vincenti,B. Nashan,G. Bumgardner,I. Hardie,M. Pescovitz,R.W.G. Johnson,for the phase III Daclizumab Study Group
Three year outcome of the phase III clinical trials with daclizumab
Transplantation, 69 (2000), pp. S261
Kirkman RL, Vincenti F, Pescovitz MD. A phase I/II randomized doubleblind placebo-controlled study of Zenapax in combination with Cellcept, Neoral and steroids. Nutley, USA: Hoffman La Roche Inc., 1998.
F. Vincenti,J. Grinyo,E. Ramos,B. Nashan,F. Stuart,D. Kuypers
Can antibody prophylaxis allow sparing of other immunosuppressives
Transplant Proc, 31 (1999), pp. 1246-1248
J. Lacha,M. Simova,L. Noskova,V. Teplan,S. Vitko
Zenapax versus OKT3 prophylaxis in immunologically high-risk kidney transplant recipients [resumen]
Transplantation, 69 (2000), pp. S158
M.H. Deierhoi,S.L. Hudson,R.S. Gaston
Clinical experience with a two dose regimen of daclizumab in cadaveric renal transplantation [resumen]
Transplantation, 69 (2000), pp. S260
G.J. Chang,R. O’Rourke,I. Lee,P.G. Stock,F. Vincenti
One or two doses of daclizumab provide effective immunosuppression for renal transplant patients with high immunologic risk or with delayed graft function [resumen]
Transplantation, 67 (1999), pp. S149
M. Millan,M. Pavlakis,E. Alfrey,O. Salvatierra,D. Dafoe,J. Scandling
A two dose regimen of daclizumab (Zenapax) in high-risk renal transplant recipients [resumen]
Transplantation, 67 (1999), pp. S84
H.U. Meier-Kriesche,G.S. Friedman,S. Palekar,H. Kaza,S.P. Mulgaonkar,B. Kaplan
Daclizumab decreases acute rejection in african american and hispanic renal transplant recipients [resumen]
Transplantation, 69 (2000), pp. S156
M.S. Golconda,S.C. Rayhill,L.G. Hunsicker
Daclizumab permits delayed introduction of calcineurin inhibitors in renal transplant recipients at risk for delayed graft funtion [resumen]
Transplantation, 69 (2000), pp. S158
C. Siegel,J. Mead,J. Buell,A. Yoshida,K. Newell,E.S. Woodle
Comparison of daclizumab vs ATGAM induction in kidney pancreas transplantation [resumen]
Transplantation, 67 (1999), pp. S223
R.J. Stratta,R.R. Alloway,E. Hodge,for the PIVOT Study Group
An open-label comparative trial of two daclizumab dosing strategies versus no antibody induction combined with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney/pancreas recipients: interim analysis [resumen]
Transplantation, 69 (2000), pp. S408
Correspondencia: Dr. J. Pascual. Servicio de Nefrología. Hospital Ramón y Cajal. Ctra. de Colmenar, km 9,100. 28034 Madrid. (Julio Pascual jpascual@hrc.insalud.es)
Copyright © 2001. Elsevier España, S.L.